title: Antibody-targeted polymer-doxorubicin conjugates with pH-controlled activation.
abstract: The paper is dealing with the synthesis and properties of new non-targeted or antibody-targeted polymer drug conjugates, bearing doxorubicin (DOX) attached via a spacer susceptible to pH-controlled hydrolysis (hydrazone conjugates), designed as anticancer drugs facilitating site-specific therapy. These conjugates are stable in a pH 7.4 buffer, modeling conditions during transport in the body, but release DOX and activate it inside target cells as a result of pH changes when going from outside to inside the cells. Conjugates containing an antibody directed against T lymphocytes bind effectively and specifically T cell lymphoma EL 4 cells. Cytotoxicity of the hydrazone conjugates is higher than that of classic conjugates, depending on the detailed structure of the polymer, the spacer between the drug and polymer carrier and method of antibody conjugation. Cytotoxicity of some of the conjugates is comparable even with that of the free drug. In both protective and therapeutic regimes of drug administration, the in vivo anti-tumor activity of the conjugates containing DOX was enhanced with long-term survivors (T-cell lymphoma EL 4, C57BL/6 mice) in comparison with much less effective free DOX or a classic P(N-(2-hydroxypropyl)methacrylamide)HPMA-DOX conjugate (already clinically tested).
authors.affiliation: Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic. ulbrich@imc.cas.cz
authors.forename: K
authors.initials: K
authors.lastname: Ulbrich
authors.forename: T
authors.initials: T
authors.lastname: Etrych
authors.forename: P
authors.initials: P
authors.lastname: Chytil
authors.forename: M
authors.initials: M
authors.lastname: Jelínková
authors.forename: B
authors.initials: B
authors.lastname: Ríhová
mesh_terms: D000818:Animals; D000961:Antilymphocyte Serum / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry; D002626:Chemistry, Pharmaceutical; D004317:Doxorubicin / Q000008:administration & dosage* / Q000737:chemistry; D016503:Drug Delivery Systems / Q000379:methods*; D004354:Drug Screening Assays, Antitumor / Q000379:methods; D006863:Hydrogen-Ion Concentration; D016399:Lymphoma, T-Cell / Q000188:drug therapy; D051379:Mice; D008810:Mice, Inbred C57BL; D011108:Polymers / Q000008:administration & dosage* / Q000737:chemistry
chemical_list: D000961:Antilymphocyte Serum; D000970:Antineoplastic Agents; D011108:Polymers; D004317:Doxorubicin